FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					OI \	<u> </u>	30(ii) oi tile	iiiveStille	- TILL C	ompany Act	01 1940						
Name and Address of Reporting Person* Perfetti Riccardo						2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [APLT]								5. Relationship of Reportin (Check all applicable) Director • Officer (give title			10% Owner	
(Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC. 545 5TH AVENUE, SUITE 1400						3. Date of Earliest Transaction (Month/Day/Year) 07/13/2021								X Officer (give title Other (specify below) below) Chief Medical Officer				
(Street) NEW YORK NY 10017					4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																		
1 Title of 9	Socurity (Inc		le I - No	on-Deriv		_	Deen		quired	, Di	.	of, or Be		Illy Owned		6.00	nership	7. Nature
Da				Date (Month/Da		Execution Date,		Transaction Code (Instr. 8)		Disposed Of (D) (Instr. 3,			5) Securiti Benefic Owned	ies cially Following	Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct Indirect str. 4)	of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 07/				07/13/	13/2021				M		460(1)	A	\$1.4	4 4	160		D	
Common Stock				07/13/	07/13/2021				S		460(2)	D	\$21.2	5 ⁽³⁾	0		D	
Common Stock				07/14/	07/14/2021				M		460(1)	D	\$1.4	4 4	160		D	
Common Stock				07/14/2021					S		460(2)	D	\$20.5	1(4)	0		D	
Common Stock 07/				07/15/	5/2021				M		460(1)	A	\$1.4	4 4	160		D	
Common Stock 07/15/2				2021	2021			S		460(2)	D	\$19.5	4 ⁽⁵⁾	0		D		
		7	Table II								posed of, converti			y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E	ned n Date,	4. Transa Code (I 8)	ction	5. Number of			exerci	isable and te	7. Title an Amount o Securities Underlyin Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amoun or Numbe of Shares					
Stock Option (Right to Buy)	\$1.44	07/13/2021			М			460 ⁽¹⁾	(6)		12/16/2028	Common Stock	460(1)	\$0.00	164,66	67	D	
Stock Option (Right to	\$1.44	07/14/2021			M			460 ⁽¹⁾	(6)		12/16/2028	Common	460(1)	\$0.00	164,20	07	D	

Explanation of Responses:

\$1.44

1. Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

460⁽¹⁾

2. Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

(6)

12/16/2028

- 3. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$20.8200 to \$21.4850 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above
- 4. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$20.1300 to \$20.6850 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above
- 5. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.3500 to \$19.7650 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 6. Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.

Remarks:

Buy) Stock Option

(Right to

Buy)

/s/ Shoshana Shendelman, Attorney-in-Fact

460(1)

Stock

\$0.00

07/15/2021

163,747

D

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

07/15/2021

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.